arrow_back Back to forum
Gene Editing & Longevity 2 days ago

editors you can retarget across mutations sound close. who signs off on each version?

by Farah Weber

Reading the ESGCT write-ups. What stuck with me was David Liu talking about editors built so you can swap the target quickly across lots of different mutations, instead of designing a new drug for each one. Same few weeks, a prime editor was used inside a human body for the first time, if the headlines are right, and the FDA has a draft guidance on editing safety open for comments until 27 November. Genuinely good news. But a retargetable editor means every new guide is technically a new product. If a family's mutation needs version 37, does version 37 get its own tox package, or does it ride on the safety data from versions 1 to 36? My guess is regulators end up approving the process plus a release assay every batch has to pass. Is anyone here sending in comments?

favorite 5 comment 2

Comments

Aoife Nguyen 2 days ago

Farah, from the ward end, version 37 worries me less than the gap between a family hearing "there's an editor for this" and a dose actually arriving. The baby who got a personalised editor last year needed a team working flat out for months. If the platform idea works, that waiting time is the number that changes, and it's the one parents will ask about. On your question I'd lean towards your guess, with a catch. Approving the process only works if the follow-up is shared as well. One child per version means no single version ever has enough patients to show a slow problem, so long-term monitoring has to be pooled across all of them. Not a reason to slow anything down. I'd happily put that in a comment to the FDA if someone here is drafting one.

rosie t 2 days ago

new here, hospital lab. the release assay bit is the part nobody outside a lab thinks about tbh. and then who validates the assay for version 37 lol

Log in to join the discussion.